GMEDStock
Verdicts genuinely change. Free email alert the moment GMED's does — no target price to set, unlike a price alert.
Stable Ratio screen, 7 of 7 decided standards passing. No standard's deciding ratio sits within 3 points of its line. What would change it
Whether this company clears the published standards, and the filings behind that answer. The screen runs first and nothing on the trading side can override it.
Structure, momentum, positioning and levels. Separate from the Sharia verdict above, which this side never overrides.
Trade setup
Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.
Trade plan
Posted with a stop, a target and the level that invalidates it. It resolves into the public record either way.
Why this signal?
The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.
GMED is currently considered halal (Sharia-compliant), per our in-house ratio engine. See the full ratio breakdown and business-activity screen below for the reasoning.
This sits among 435 compliant Healthcare stocks we track. See compliant Healthcare stocks →
How the status reached this point
Compliant · status tracked since Nov 17, 2026
No change to GMED’s published status has been recorded since our daily status check began on Nov 17, 2026. What it read before then is not on record here.
Read once a day from the status this page publishes, last on Nov 20, 2026. The per-methodology record is under “What changed, and when” in the in-house research.
🕌 In-house Compliance Research
Computed from published company financials, balance sheet as of 2026-09-30. These ratios come from the issuer's own published statements rather than structured SEC data.
AAOIFI divides by the market cap: $9.3B as of 2026-11-17. At the 2026-11-20 close it is about $9.2B (the stored market cap moved by the share price since, not a new share count), and at that cap AAOIFI's interest-bearing debt ratio would read 1.2% (1.2% at the stored cap, against a 30% line) and interest-bearing investments ratio would read 6.1% (6.0% at the stored cap, against a 30% line). The published verdict changes only when the company is re-screened.
Business activity: cleared (no excluded categories detected)
AAOIFI Pass 3 of 3 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 1.15% | 30.00% | Pass(28.8pp buffer) |
| Interest-bearing investments | 6.04% | 30.00% | Pass(24.0pp buffer) |
| Non-permissible income | 0.00% | 5.00% | Pass(5.0pp buffer) |
Usmani Pass 5 of 5 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 1.96% | 33.00% | Pass(31.0pp buffer) |
| Interest-bearing investments | 10.20% | 33.00% | Pass(22.8pp buffer) |
| Non-liquid assets | 77.58% | at least 20.00% | Pass(57.6pp above the floor) |
| Non-permissible income | 0.00% | 5.00% | Pass(5.0pp buffer) |
| Net liquid assets per share | $731.2M | under mkt cap $9.3B | Pass |
MSCI Pass 4 of 4 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 1.95% | 33.33% | Pass(31.4pp buffer) |
| Cash + interest-bearing securities | 10.20% | 33.33% | Pass(23.1pp buffer) |
| Accounts receivable | 22.42% | 33.33% | Pass(10.9pp buffer) |
| Non-permissible income | 0.00% | 5.00% | Pass(5.0pp buffer) |
FTSE Pass 4 of 4 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.00% | 33.33% | Pass(33.3pp buffer) |
| Cash + interest-bearing securities | 10.20% | 33.33% | Pass(23.1pp buffer) |
| Accounts receivable | 22.42% | 50.00% | Pass(27.6pp buffer) |
| Non-permissible income | 0.00% | 5.00% | Pass(5.0pp buffer) |
Dow Jones Islamic Market Pass 4 of 4 ratios pass
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 1.00% | 33.00% | Pass(32.0pp buffer) |
| Cash + interest-bearing securities | 5.22% | 33.00% | Pass(27.8pp buffer) |
| Accounts receivable | 6.25% | 33.00% | Pass(26.7pp buffer) |
| Non-permissible income | 0.00% | 5.00% | Pass(5.0pp buffer) |
S&P Shariah Pass 4 of 4 ratios pass
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 1.07% | 33.00% | Pass(31.9pp buffer) |
| Cash + interest-bearing securities | 5.62% | 49.00% | Pass(43.4pp buffer) |
| Accounts receivable | 6.73% | 49.00% | Pass(42.3pp buffer) |
| Non-permissible income | 0.00% | 5.00% | Pass(5.0pp buffer) |
MSCI M-Series Pass 4 of 4 ratios pass
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 1.07% | 33.33% | Pass(32.3pp buffer) |
| Cash + interest-bearing securities | 5.62% | 33.33% | Pass(27.7pp buffer) |
| Accounts receivable | 12.36% | 49.00% | Pass(36.6pp buffer) |
| Non-permissible income | 0.00% | 5.00% | Pass(5.0pp buffer) |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
How close is it to flipping?
Every current reading against its own line, closest first. A verdict is only as durable as that distance.
The numbers the ratios are built from
Read from GMED's own filings. Every percentage on this page is one of these lines divided by another, so the inputs are shown rather than asserted.
| Line | Figure | As reported | Read from |
|---|---|---|---|
| RevenueTotal revenue for the period | $2.9B | 2026-09-30 | Revenues |
| Interest-bearing debtShort and long-term borrowings | $0 | 2026-09-30 | no debt tag reported in 3+ years (treated as $0) |
| Cash and interest-bearing securitiesCash, equivalents and marketable securities | $563.9M | 2026-09-30 | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents, MarketableSecuritiesCurrent |
| Total assetsBalance sheet total | $5.5B | 2026-09-30 | Assets |
| Market capDenominator for AAOIFI | $9.3B | live quote | price x shares |
| 36-month average market capDenominator for S&P Shariah and MSCI M-Series | $9.7B | 756 trading days | closes x shares |
| 24-month average market capDenominator for Dow Jones Islamic Market | $10.4B | 504 trading days | closes x shares |
| Non-permissible revenueInterest and excluded income | $0 | 2026-09-30 | no interest-income tag reported in 3+ years (treated as $0) |
Two dates, not one: a balance-sheet line and an income-statement line cover different windows by design, so each figure carries its own.
Sources
Filing information. Balance sheet: Quarterly report (10-Q) filed 2026-11-05, period ended 2026-09-30. Income statement: Annual report (10-K) filed 2026-02-24, period ended 2026-09-30. Screened 2026-11-17.
-
Total assets$5.5B
Assets· period ended 2026-09-30 · 10-Q filed 2026-11-05 -
Interest-bearing debt$0
no debt tag reported in 3+ years (treated as $0)· balance sheet as of 2026-09-30 · no filing link for this figure -
Cash and interest-bearing securities$563.9M
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents$487.7M · period ended 2026-09-30 · 10-Q filed 2026-11-05MarketableSecuritiesCurrent$76.2M · period ended 2026-09-30 · 10-Q filed 2026-11-05 -
Receivables$675.3M
AccountsReceivableNetCurrent· period ended 2026-09-30 · 10-Q filed 2026-11-05 -
Revenue$2.9B
Revenues· period ended 2025-12-31 · 10-K filed 2026-02-24 -
Interest income (non-permissible)$0
no interest-income tag reported in 3+ years (treated as $0)· income statement as of 2026-09-30 · no filing link for this figure -
Market cap$9.3BYahoo Finance quote, 2026-11-17 · not a filing figure, so no link
5 reported values cited from 2 SEC filings, read from SEC's XBRL company facts when this symbol was screened. A link opens the filing's index on EDGAR.
What changed, and when
Verdict history for GMED. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.
- 2026-09-07 No change recorded No verdict change for GMED has been recorded since tracking began. The scan ledger records that the compliance detectors ran, not which symbols each pass covered.
Tracked since 2026-09-07.
Revenue by business segment
How GMED’s $2.9B of revenue for the fiscal year 2025-01-01 to 2025-12-31 splits across what it sells, as the company tags it in its own 10-K.
| Segment | Share | Revenue |
|---|---|---|
| Musculoskeletal Solutions | 95.2% | $2.8B |
| Enabling Technologies | 4.8% | $141.0M |
These are the company’s own segment names and figures. They do not say whether a line of business is permissible; our business-activity screen does.
Source: 10-K filed 2026-02-24 (accession 0001628280-26-011209), read from its XBRL on SEC EDGAR. Shares are of total revenue; subtotals and overlapping cuts the filing also tags are left out, so the lines add up to the total.
What would change the status
The headline verdict is the majority of the decided ratio standards — 7 pass and 0 fail of 7 — with a business-activity screen and any hold applied on top. Balance sheet as of 2026-09-30; market cap as stored on 2026-11-17.
No standard's deciding ratio sits within 3 points of its line.
The ratios that move with the share price
AAOIFI's debt ratio (1.2% against a 30% line) would only fail if the market cap fell by 96%, to $358.5M. At the 2026-11-20 close it would read 1.2%.
AAOIFI's investments ratio (6.0% against a 30% line) would only fail if the market cap fell by 80%, to $1.9B. At the 2026-11-20 close it would read 6.1%.
Only AAOIFI divides by the market cap itself. The Dow Jones, S&P and MSCI M-Series standards divide by a 24- or 36-month average and the others by total assets, so a day's price move does not reach them. Figures are the screen's own; the live market cap differs from the stored one.
Shariah-compliant alternatives
Compliant companies in Medical Devices listed on the same market, largest first. Each is screened on its own; none carries a documented concern or a hold.
| Company | Market cap | Price, day |
|---|---|---|
| ABTAbbott Laboratories | $201.9B | — |
| SYKStryker Corp. | $125.7B | — |
| MDTMedtronic Plc | $117.8B | — |
| BSXBoston Scientific Corp. | $71.0B | — |
| EWEdwards Lifesciences Corp | $52.2B | — |
A dash means no fresh quote is cached for that symbol; this list does not fetch one.
Funds that hold GMED
12 of the 277 funds whose filed holdings we currently hold own GMED shares. That set is a fixed list of widely held index funds and Shariah funds, plus the funds our look-through has read most recently. It is not every fund that owns GMED.
Shariah funds| Fund | GMED in fund | Fund compliant by weight |
|---|---|---|
| MNZL Manzil Russell Halal USA Broad Market ETF | 0.03% | 88% |
Widely held U.S. index funds. If you own one, you own GMED through it. None of them is a Shariah fund; the last column is our look-through of each.
| Fund | GMED in fund | Fund compliant by weight |
|---|---|---|
| VTI VANGUARD TOTAL STOCK MARKET INDEX FUND Also VTSAX | 0.01% | 54% |
| SCHB Schwab U.S. Broad Market ETF | 0.01% | 53% |
| ITOT iShares Core S&P Total U.S. Stock Market ETF | 0.01% | 54% |
| Fund | GMED in fund | Fund compliant by weight |
|---|---|---|
| LVOTX Lord Abbett Value Opportunities Fund | 1.69% | 52% |
| GQQQ Astoria US Quality Growth Kings ETF | 0.46% | 61% |
| EVSRX Allspring Disciplined U.S. Core Fund Also EVSTX | 0.08% | 50% |
| MDDLX MassMutual Diversified Value Fund | 0.06% | 35% |
| DFAC Dimensional U.S. Core Equity 2 ETF | 0.03% | 49% |
| VSEQX VANGUARD STRATEGIC EQUITY FUND | 0.02% | 42% |
| ETTOX E*TRADE No Fee Total Market Index Fund | 0.01% | 52% |
| BBVLX Bridge Builder Large Cap Value Fund | 0.01% | 36% |
Sorted by GMED’s share of each fund, from the fund’s latest SEC N-PORT filing. “Compliant by weight” is the share of the fund’s holdings our look-through screens compliant. A fund is listed only where its filing is mostly equity and names GMED once, so a bond is not counted as the shares. Shariah funds are those with a recorded certification, on our halal ETF list, or named Shariah, Islamic, Halal or Sukuk.
| Investor | Firm | Position | Weight | As of |
|---|---|---|---|---|
| Joel Greenblatt | Gotham Asset Management | $32M | 0.1% | 2026-09-30 |
| Jeremy Grantham | GMO | $31M | 0.1% | 2026-09-30 |
| Peter Brown | Renaissance Technologies | $30M | 0.0% | 2026-09-30 |
| Ray Dalio | Bridgewater Associates | $24M | 0.1% | 2026-09-30 |
| Ken Griffin | Citadel Advisors | $16M | 0.0% | 2026-09-30 |
| Mario Gabelli | GAMCO Investors | $10M | 0.1% | 2026-09-30 |
| Israel Englander | Millennium Management | $7M | 0.0% | 2026-09-30 |
| Ruane, Cunniff & Goldfarb | Ruane, Cunniff & Goldfarb | $4M | 0.1% | 2026-09-30 |
| John Hussman | Hussman Strategic Advisors | $4M | 0.8% | 2026-09-30 |
| David Shaw | D. E. Shaw & Co. | $1M | 0.0% | 2026-09-30 |
From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
Price Forecast
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
Technical Summary
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Every indicator, and what it reads
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 35.20 | NEUTRAL |
| Stochastic %K (14) | 1.21 | BUY |
| CCI (20) | -123.26 | BUY |
| Williams %R (14) | -98.79 | BUY |
| MACD (12,26,9) | -1.15 | SELL |
| ROC (10) | -5.86 | SELL |
| Momentum (10) | -4.16 | SELL |
| EMA (10) | 71.48 | SELL |
| SMA (10) | 71.79 | SELL |
| EMA (20) | 73.94 | SELL |
| SMA (20) | 76.08 | SELL |
| EMA (30) | 75.05 | SELL |
| SMA (30) | 76.74 | SELL |
| EMA (50) | 76.22 | SELL |
| SMA (50) | 75.97 | SELL |
| EMA (100) | 78.16 | SELL |
| SMA (100) | 78.20 | SELL |
| EMA (200) | 81.82 | SELL |
| SMA (200) | 82.22 | SELL |
About GMED
Healthcare · Medical Devices
Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products comprising traditional fusion implants, such as pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices; treatment options for motion preservation technologies consisting of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and biologic solutions, such as allografts and synthetic alternatives. It also provides orthopedic trauma solutions, including limb reconstruction, fracture plating, intramedullary nailing, external fixation, and compression screw technologies; hip and knee arthroplasty solutions, including modular cement and cementless hip stems, acetabular cups, femoral heads, highly cross-linked liners, partial knee systems, cruciate retaining, posterior stabilized, and revision options; spinal cord stimulation services; and neuromonitoring services, which provide onsite and remote monitoring of the neurological systems. In addition, the company offers ExcelsiusGPS platform, a robotic guidance and navigation system for minimally invasive and open procedures; Surgimap, a surgical planning software platform; Excelsius3D, a platform combined with ExcelsiusGPS that provides an intraoperative and image-guided robotic navigation solution; ExcelsiusHub, which provides real-time patient array monitoring, tissue sparing drills, and registration flexibility; and ExcelsiusFlex, a total knee arthroplasty robotic solution. Further, it distributes human cells, tissues, and cellular and tissue-based products. The company sells its products through direct and distributor sales representatives; and independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.
Background via Yahoo Finance — informational, not part of the verdict.
Latest Signal — 2026-11-09
Stop 73.16 Now 66.89 Target 75.38
🟠 NOT YET
The main driver: lagging the market by 9.2%. More negatives than positives right now. The setup isn't ready — check back when the trend or RSI changes.
Scores: 1 bullish / 2 bearish
Weak — low conviction, small size or skip
SMC — Top Down
Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | BEARISH | 64 |
| ⏰ 4H | BEARISH | 39 |
| 🕐 1H | BEARISH | 98 |
| ⏱ 15-Min | BEARISH | 130 |
| ⏲ 5-Min | BEARISH | 234 |
Momentum & Volume
Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.
Peer Movement
How the rest of the sector moved over the same window. Context for a price move, never a cause of one.
Peer movement computing — it will appear here on its own.
Before you act on this
The questions worth asking about any verdict on this page, answered plainly.
Is this a fatwa?
No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.
Why can the standards disagree?
Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.
How often is this re-screened?
Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.
Do I need to purify dividends?
If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.
Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.
Compare with
Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.
Peer screening computing — it will appear here on its own.
Insider Activity (90d)
Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.
NO DATA 0 buys · 0 sells
COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE
The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.
NEUTRAL report date 2026-11-17 · Asset managers net 895049 (-19081)
AI Summary
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.